Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Mallinckrodt
AstraZeneca
Merck
Colorcon

Last Updated: June 29, 2022

Peramivir - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for peramivir and what is the scope of freedom to operate?

Peramivir is the generic ingredient in one branded drug marketed by Biocryst and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Peramivir has sixty-seven patent family members in twenty-eight countries.

There is one drug master file entry for peramivir.

Summary for peramivir
International Patents:67
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 1
Raw Ingredient (Bulk) Api Vendors: 75
Clinical Trials: 15
Patent Applications: 2,923
What excipients (inactive ingredients) are in peramivir?peramivir excipients list
DailyMed Link:peramivir at DailyMed
Recent Clinical Trials for peramivir

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hoffmann-La RochePhase 3
Department of Health and Human ServicesPhase 4
Johns Hopkins UniversityPhase 4

See all peramivir clinical trials

US Patents and Regulatory Information for peramivir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for peramivir

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Biocryst Alpivab peramivir EMEA/H/C/004299
Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Withdrawn no no no 2018-04-13
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Baxter
Colorcon
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.